Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bioorthogonal Self-Immolative Linker Based on Grob Fragmentation

  • Ferhati, Xhenti
  • Salas-Cubero, Marina
  • Garrido, Pablo
  • García-Sanmartín, Josune
  • Guerreiro, Ana
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Peregrina, Jesús M.
  • Martínez, Alfredo
  • Jiménez-Moreno, Ester
  • Bernardes, Gonçalo J. L.
  • Corzana, Francisco
A self-immolative bioorthogonal conditionally cleavable linker based on Grob fragmentation is described. It is derived from 1,3-aminocyclohexanols and allows the release of sulfonate-containing compounds in aqueous media. Modulation of the amine pKa promotes fragmentation even at slightly acidic pH, a common feature of several tumor environments. The Grob fragmentation can also occur under physiological conditions in living cells, highlighting the potential bioorthogonal applicability of this reaction., We thank the Agencia Estatal de Investigación of Spain (AEI; Grant No. RTI2018-099592−B-C21). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 675007. M.S.-C. thanks the Asociación Española Contra el Cáncer AECC (La Rioja) for the predoctoral fellowship. E.J.-M. acknowledges the contract Beatriz Galindo from the Ministry of Universities of Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Single Mutation on Trastuzumab Modulates the Stability of Antibody−Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry

  • Ferhati, Xhenti
  • Jiménez-Moreno, Ester
  • Hoyt, Emily A.
  • Salluce, Giulia
  • Cabeza-Cabrerizo, Mar
  • Navo, Claudio D.
  • Compañón, Ismael
  • Akkapeddi, Padma
  • Matos, Maria J.
  • Salaverri, Noelia
  • Garrido, Pablo
  • Martínez, Alfredo
  • Laserna, Víctor
  • Murray, Thomas V.
  • Jiménez-Osés, Gonzalo
  • Ravn, Peter
  • Bernardes, Gonçalo J. L.
  • Corzana. Francisco
Antibody-drug conjugates (ADCs) are a class of targetedtherapeutics used to selectively kill cancer cells. It is important that theyremain intact in the bloodstream and release their payload in the targetcancer cell for maximum efficacy and minimum toxicity. The development ofeffective ADCs requires the study of factors that can alter the stability of thesetherapeutics at the atomic level. Here, we present a general strategy thatcombines synthesis, bioconjugation, linker technology, site-directed muta-genesis, and modeling to investigate the influence of the site andmicroenvironment of the trastuzumab antibody on the stability of theconjugation and linkers. Trastuzumab is widely used to produce targeted ADCs because it can target with high specificity a receptorthat is overexpressed in certain breast cancer cells (HER2). We show that the chemical environment of the conjugation site oftrastuzumab plays a key role in the stability of linkers featuring acid-sensitive groups such as acetals. More specifically, Lys-207,located near the reactive Cys-205 of a thiomab variant of the antibody, may act as an acid catalyst and promote the hydrolysis ofacetals. Mutation of Lys-207 into an alanine or using a longer linker that separates this residue from the acetal group stabilizes theconjugates. Analogously, Lys-207 promotes the beneficial hydrolysis of the succinimide ring when maleimide reagents are used forconjugation, thus stabilizing the subsequent ADCs by impairing the undesired retro-Michael reactions. This work provides newinsights for the design of novel ADCs with improved stability properties., We thank the Agencia Estatal Investigación of Spain (AEI; Grants RTI2018-099592-B-C21 to F.C. and RTI2018-099592- B-C22 to G.J.-O.). This project has received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 675007. E.J.-M. thanks Universidad de la Rioja for a postdoctoral fellowship and Ministerio de Universidades of Spain for a Beatriz Galindo fellowship (BG20/00103) M.J.M. thanks Xunta da Galicia (Plan I2C-ED481B 2014/086-0 and ED481B 2018/007). M.C.-C. thanks Schmidt Science Fellow- ship program. G.S. thanks MINECO for her F. P. I. fellowship (PRE2018-085973). C.D.N. and G.J.-O. thank the Agencia Estatal de Investigacion for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644). We also thank AstraZeneca for providing the antibodies used in this study., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Structure-Based Design of Potent Tumor-Associated Antigens: Modulation of Peptide Presentation by Single-Atom O/S or O/Se Substitutions at the Glycosidic Linkage

  • Companión, I.
  • Guerreiro, A.
  • Mangini, V.
  • Castro-López, J.
  • Escudero-Casao, M.
  • Avenoza, A.
  • Busto, J.H.
  • Castillón, S.
  • Jiménez-Barbero, J.
  • Asensio, J.L.
  • Jiménez-Osés, G.
  • Boutureira, O.
  • Peregrina, J.M.
  • Hurtado-Guerrero, R.
  • Fiammengo, R.
  • Bernardes, G.J.L.
  • Corzana, F.
GalNAc-glycopeptides derived from mucin MUC1 are an important class of tumor-associated antigens. a-O-glycosylation forces the peptide to adopt an extended conformation in solution, which is far from the structure observed in complexes with a model anti-MUC1 antibody. Herein, we propose a new strategy for designing potent antigen mimics based on modulating peptide/carbohydrate interactions by means of O â†'' S/Se replacement at the glycosidic linkage. These minimal chemical modifications bring about two key structural changes to the glycopeptide. They increase the carbohydrate-peptide distance and change the orientation and dynamics of the glycosidic linkage. As a result, the peptide acquires a preorganized and optimal structure suited for antibody binding. Accordingly, these new glycopeptides display improved binding toward a representative anti-MUC1 antibody relative to the native antigens. To prove the potential of these glycopeptides as tumor-associated MUC1 antigen mimics, the derivative bearing the S-glycosidic linkage was conjugated to gold nanoparticles and tested as an immunogenic formulation in mice without any adjuvant, which resulted in a significant humoral immune response. Importantly, the mice antisera recognize cancer cells in biopsies of breast cancer patients with high selectivity. This finding demonstrates that the antibodies elicited against the mimetic antigen indeed recognize the naturally occurring antigen in its physiological context. Clinically, the exploitation of tumor-associated antigen mimics may contribute to the development of cancer vaccines and to the improvement of cancer diagnosis based on anti-MUC1 antibodies. The methodology presented here is of general interest for applications because it may be extended to modulate the affinity of biologically relevant glycopeptides toward their receptors.